The ongoing challenge, Liu said, is to decide which women need additional therapy. Importance of this particular study shows that there’s an advantage to incorporate a Taxenne in adjuvant treatment for some women with breast cancer without lymph node involvement.Dr. Minetta Liu, director of translational research in breast cancer Lombardi Comprehensive Cancer Center at Georgetown University, said that the new study confirms what many oncologists already do.
are diagnosed with skin cancer each year., research assistant professor at Stritch. There are various surgical treatments, including simple excision and electrodessication curettage and cryosurgery .
Even so, he said, I believe that this study provides reason to believe this plan, especially for women at high risk of breast cancer without lymph node involvement.
For more information on the treatment of breast cancer, visit the U. S. National Cancer Institute.
The TAC regimen was better to keep alive the women without the disease after a median follow-up of almost six and a half years, the study found.
However, adverse drug events were more frequent with TAC of 28 % of patients, compared with 17 % of patients with acute coronary syndrome.
Many oncologists are incorporating Taxenne [such as docetaxel] in the adjuvant treatment of breast cancer without lymph node involvement, said Liu, who has examined the results of the study, but did not participate in the research.
The risk reduction was true even after controlling for a number of high risk factors such as age, menopausal status of women if the tumor characteristics.
TAC is more toxic, Martin said, adding that all the toxic effects were reversible. A common side effect was neutropenia, an abnormally low numbers of white blood cells. Fatigue was also a problem, the study found.
Chemotherapy has shown superior to other treatments for breast cancer that has spread to lymph nodes may also work better for some women whose cancer spreads paradise, a new study has found.
SOURCES: Miguel Martin, MD, Ph.D., Professor of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Minetta Liu, MD, director of translational research, Lombardi Comprehensive Cancer Center, Georgetown, Washington, DC, New England Journal of Medicine, December 2, 2010
The study was funded by the pharmaceutical company Sanofi-Aventis’ Taxotere is the brand name for docetaxel and GEICAM, the research group on breast cancer in Spanish. The findings are published in the Dec. 2 issue of the New England Journal of Medicine.
For the new study, researchers assigned 1,060 women with breast cancer who had negative axillary lymph nodes have at least a factor of high risk of recurrence in one of two regimens every three weeks for six cycles after surgery.
To determine which women with breast cancer may benefit from adjuvant chemotherapy , doctors take into account a number of risk factors such as the patient’s age, size and other characteristics of the tumor.